Immunome Appoints New Management

Three Proven Industry Veterans Join the Strong Scientific Team

Positions Immunome for Long Term Growth

WYNNEWOOD, Pa.--(BUSINESS WIRE)--Immunome, Inc., a biotechnology company with a unique and powerful immunotherapy discovery engine for new cancer targets and therapeutics, announces the appointment of three new members to its management team, Jane H. Hollingsworth as executive chair; Joan Lau, PhD as chief operating officer and Joel F. Sussman as chief financial officer.

Michael Widlitz, the company's lead director, said, "Jane, Joan and Joel bring top tier industry, operational and scientific management experience to the strong scientific team already in place. The addition of this elite group demonstrates the commitment of the board and investors to advancing its unique, paradigm-shifting cancer immunotherapy technology. We are delighted to welcome them to the management team. With their leadership and proven expertise, look forward to a very bright future for the company."

Ms. Hollingsworth is a 20 year veteran of the pharmaceutical industry and a proven leader in the field. She is founder and managing partner of Militia Hill Ventures, a life sciences accelerator; founder and former chief executive officer of NuPathe (PATH); founder and former executive vice president of Auxilium Pharmaceuticals (AUXL) and former executive vice president and general counsel of IBAH, a multinational clinical research organization (IBAH). Ms. Hollingsworth serves on a number of industry and civic boards and is a leader in building the life sciences industry in the mid-Atlantic region.

Ms. Hollingsworth earned an undergraduate degree from Gettysburg College and a JD from Villanova University.

Dr. Lau is founder and managing partner of Militia Hill Ventures and former president and chief executive officer of two venture-backed biotechnology companies, Azelon Pharmaceuticals and Locus Pharmaceuticals. Previously, Dr. Lau held roles of increasing responsibility in drug discovery and development and business development at Merck & Co., Inc. Dr. Lau is also associate course director for the Vagelos Program in Life Sciences Management at the University of Pennsylvania and formerly served as executive-in-residence at BioAdvance, a funder of life sciences companies in southeastern Pennsylvania.

Dr. Lau earned an undergraduate degree in bioengineering from the University of Pennsylvania, an MBA from the Wharton School of the University of Pennsylvania and a PhD in Neuroscience from the University of Cincinnati College of Medicine.

Mr. Sussman is a financial management consultant who serves as chief financial officer for early-stage life sciences companies. His present and former clients include numerous venture-backed life sciences and technology companies, including one that he joined to take the company public and serve as its full-time chief financial officer until its sale to a larger public company. Before beginning his consulting practice in 1995, he had fifteen years experience as chief financial officer and/or treasurer of public and private technology and healthcare companies.

Mr. Sussman earned an undergraduate degree from Yale and an MBA from the Wharton School of the University of Pennsylvania and is a licensed certified public accountant.

About Immunome

Immunome is a biotechnology company with a unique and powerful immunotherapy discovery engine for new cancer targets and therapeutics. The proprietary technology and methods, originally discovered at MIT's Whitehead Institute, enable Immunome to simultaneously discover novel cancer antigens and isolate native human antibodies that attack cancer cells. The technology is a highly efficient immunotherapy discovery engine, enabling the discovery of cancer antigens and antibodies in only a few months, as opposed to the four or more years with current discovery methods. No other platform provides such a rapid and productive means for identifying and advancing the newest cancer treatments.


Joel F. Sussman
Chief Financial Officer
[email protected]

Suggested Articles

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.  

The deal is worth $50 million upfront but could balloon in value to more than $2 billion if all the milestones are hit.